Treatments of Metachronous Liver Metastases From Colorectal Cancer

Clinicopathological variables and p53 overexpression as a combined prognosticator for hematogenic recurrence in colorectal cancer

“…Hematogenic recurrence developed within 2 years of the initial surgery in 72% (13/18), 62% (8/13), 77% (10/ 13) of the combined p53+/n+, p53+/v+, or p53+/CEA+ groups, respectively. Generally, 70% of patients who developed hematogenic recurrence are diagnosed within 2 years of the initial surgery [14]. An acceptable prognosis can be obtained in patients who are detected with hematogenic recurrence at an early stage and undergo resection for the recurrent tumor: e.g., the 5-year survival rates for patients with hepatic resection are up to 30-40% [15,16] and those with lung resection are up to 24-40.5% [17,18], respectively.…”